Last quarter more Institutions decreased their postions vs. Increasing them
shares Increased Positions 11,428,927
shares Decreased Positions 23,657,815
Source NASDAQ website
Smart money is getting out. Since churn, burn and chop strategies are very short sighted ways to juice a stock only for the gain of upper management and them getting their stock options excerised. TIMBER nowhere to go but down from here...Sales keep going down every quarter !!! What the Blank??? lol
No growth here only sales decreases across the board. The short term gains of financial engineering only nets in the end long term pain and damage with shrinking market share. Good Job JB!
Sentiment: Strong Sell
Well hey look you may have been right..Good for you... but there was a lot of smart money in this so normally I err on the side of smart money who do a lot of research. I will wait and see what Nadine Wong has to say if she dumps I will dump.... and I will take my lumps... that is why a shot gun approach to Biotech investing is always the best path to take.
Data looked good all along ....so for now stay the course and lets see where this winds up when data is fully analyzed...oh the fun of biotech investing ...it is a wild ride ..and sometimes hurts...
This is no high tech company or biotech?
GILD has a 10 PE? AAPL has a 12 PE ?
And this pig has a 20 PE?
Lots of smoke, mirrors here and hot air !!
Abbots Abosrb has Blood clots twice as high as aposed to DES stents ...
hey ding #$%$ ice ice baby aka loser .. the CEO is a very honorable guy as a matter of fact does not make $ 5 million a year...he in fact he put up his own money to buy more stock in the open market ...
Well my friend If you are going to rely on the writings of other people on a Yahoo message board for your information I feel sad for you ! You have to do your own work because people can and will post things that are not accurate and if you do not do your own work and fact find yourself you will get burnt ... And yes that is good neighborly advice... Good luck you will need it.
Dude you need to go back and do your own due diligence it is all here if you do the work
no dummy the most it can go down is another .28 cents ...hey why don't you short the stock?
The most it can go is .28...lol....however I would say there there is a lot more upside than downside....Most people are not buying it here for earnings in case you did not realize that.
I guess I know why now the stock was under pressure...
Well these guys better execute now for sure.. I believe the story ...now it is time to execute and get sales.! We better get some good sales results going forward and a partner for DES. Hanging tight at this point no reason to sell down here.
NSPR has a unique patented mesh technology for stents. There has been no innovation in stents for over 15 years. Premium price soild sales ramping up in Europe. Major Docs in Europe are supporting this new stent with a mesh. The clinical data to date looks very compelling with a P value of .03 ....So it is stat sig. They should easily be able to gain 20% ..30% of the European market which is $500 million. Over here with a partner on DES stents that is a multi billion dollar market place this looks like a $500 million dollar a year company to me in the early stages that someone could snap up on the cheap for $4 bucks a sharewhich puts it at $168 market cap or even $8 a share which puts it at $336 million. Any BSX folks have any thoughts? The guy running NSPR is an ex-Executive from BSX?
NSPR has a unique patented mesh technology for stents. There has been no innovation in stents for over 15 years. Premium price soild sales ramping up in Europe. Major heart Docs in Europe are supporting this new stent with a mesh. The clinical data to date looks very compelling with a P value of .03 ....So it is stat sig. They should easily be able to gain 20% ..30% of the European market which is $500 million. Over here with a partner on DES stents that is a multi billion dollar market place this looks like a $500 million dollar a year company to me in the early stages that even some other company snap up even now on the cheap at $4 bucks a share puts it at $168 market cap $8 a share puts it at $336 million.
NSPR has some new exciting stent technology that is patented and 2 years ahead of anybody else?
just trying to my self a call to IR...hopefully we will hear some good news about guidance for this year on sales....